STAT September 17, 2025
Some experts question whether staffing cuts could undermine agency’s effort
WASHINGTON – In an unprecedented move, federal regulators published about 100 warning letters sent to pharmaceutical companies and health care providers, ordering them to stop or alter ads or other promotions the government considered misleading.
The letters went to major drugmakers like Novartis and Eli Lilly, and to telehealth firms like Hims & Hers, shortly after the Trump administration announced the advertising crackdown. But...
Today's Sponsors
Today's Sponsor